MétaCan
Menu
← Back to cohort
Record W4283710103 · doi:10.1017/cjn.2022.269

Axial Improvement after Casirivimab/Imdevimab Treatment for COVID-19 in Parkinson’s Disease

2022· letter· en· W4283710103 on OpenAlexvenueno aff
Valentina Fioravanti, Francesco Cavallieri, Alessio Di Fonzo, Giulia Toschi, S. Grisanti, Gaetano Salomone, Mario Zappia, Franco Valzania

Bibliographic record

VenueCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2022
Typeletter
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsCoronavirus disease 2019 (COVID-19)Medicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Parkinson's diseaseBetacoronavirusDiseasePandemicVirologyInternal medicineOutbreakInfectious disease (medical specialty)

Abstract

fetched live from OpenAlex

We report the case of a patient with advanced Parkinson's disease (PD) who developed significant improvement of freezing of gait (FOG) after receiving monoclonal antibodies cocktail casirivimab/Imdevimab (REGN-COV2, Regeneron-Roche) for the treatment of COVID-19 infection.A 70-year-old PD patient started at the age of 47 with rigidity and bradykinesia in the left foot.At 63, his symptoms were not well controlled with severe motor fluctuations, peak-dose dyskinesia, and levodopa-responsive FOG, so he was treated with bilateral subthalamic deep brain stimulation.His motor conditions considerably improved after surgery with the disappearance of motor fluctuations and FOG and marked reduction of dyskinesia.However, after 5 years, he progressively complained severe FOG, also after levodopa intake, with instability and rare falls together with mild peak-dose dyskinesia.In August 2021, he developed cough and myalgia and was diagnosed with mild COVID-19 infection after a positive nasopharyngeal swab for SARS-CoV-2.The patient was not vaccinated for COVID-19 before.In the very first days of infection, COVID-19 infection, PD symptoms did not worsen nor the patient required hospitalization.However, since the patient was considered to be at high risk of progressing to severe COVID-19 infection, he was immediately treated with a single intravenous infusion of REGN-COV2 (total dose: 2.4 g).No further drugs were administered except paracetamol.After REGN-COV2 infusion COVID-19 symptoms disappeared in few days.No changes were made to stimulation parameters or pharmacological daily treatment (levodopa/carbidopa 100/25 mg four tabs; rotigotine patch 6 mg; selegiline 5 mg).The day after REGN-COV2 infusion, he noticed a marked improvement of gait, particularly of FOG, and moderate improvement of speech.The benefits on walking remained unchanged for over 2 weeks (Video, segments 1, 2), then gradually reduced, and disappeared after about 40 days (Video, segment 3), as well as speech improvement.REGN-COV2 is an antibody cocktail containing two neutralizing human IgG1 SARS-CoV-2-neutralizing antibodies, recently

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Case report · Consensus signal: Case report
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.014

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.000
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0040.003
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.050
GPT teacher head0.301
Teacher spread0.251 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designCase report
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques→Same topicParkinson's Disease Mechanisms and Treatments→French-language works237,207→